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THE PEOPLE’S 
RESEARCH PROJECT
Each year Australians invest more than 
half a billion dollars in health and 
medical research, and it seems even 
this is not enough! 
A recent public opinion poll by 
Research Australia (a non-profit 
organisation dedicated to raising the 
profile of health and medical research) 
showed that most Australians not only 
consider such research to be vital, but 
also believe that government funding 
should be increased. Of some surprise 
is the finding that most Australians are 
prepared to pay an extra dollar on 
medical prescriptions provided that it 
is used for research.
But what do Australians want for 
their money? 
At a recent “talkfest” on setting 
the agenda for health and medical 
research, a prominent academic 
offered the opinion that the public 
does not care, and that setting research 
priorities is the business of 
governments and the scientific 
community. Although challenged on 
his view, there is some truth in his 
assertion. Indeed, the National Health 
and Medical Research Council 
Strategic Plan 2003–2006 states that 
“the research priorities have been 
identified by Government, Council 
and major stockholders.”  Whether a 
major stockholder is the public is not 
clear. But, there is another idea. 
In his recent essay Set them free, 
Rupert Sheldrake, biologist and 
science commentator, argues that it is 
time to ask what the public wants and 
to address how money is spent 
according to agendas set by scientists 
and government bureaucracies. His 
solution? An experiment: devote one 
per cent of the annual research budget 
to “research of real interest to lay 
people, who pay for all publicly-
financed research through taxes.”
The People’s Research Project! Now 
there’s a challenge for the National 
Health and Medical Research Council.
Martin B Van Der Weyden
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Letters
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Jeff Wassertheil,§ Vic Callanan,¶ John Hall** 
(ARC executive committee on behalf of 
the Australian Resuscitation Council)
* Chairman, Australian Resuscitation Council, 
C/- Royal Australasian College of Surgeons, Spring 
Street, Melbourne, VIC 3000; † Physician, Intensive 
Care Unit, Royal Children’s Hospital, Melbourne, VIC; 
‡ Nurse Unit Manager, Central Gippsland Health 
Service, Sale, VIC; § Director of Emergency Medicine, 
Peninsula Health, Frankston, VIC; ¶ Head, 
Anaesthesia, Townsville Hospital, Townsville, QLD; 
** Superintendent, Divisional Office, Ambulance 
Service of NSW, Hurstville, NSW. 
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TO THE EDITOR: With the increasing
availability of biphasic defibrillators for
use in both the manual and shock-
advisory modes, considerable confusion
has developed as to the appropriate
energy levels to be used with these
devices. This confusion has arisen
partly because of differing recommen-
dations from manufacturers, partly as a
result of limited clinical evidence and
partly because of the clinical availability
of both monophasic and biphasic defi-
brillators. The differences between
these waveforms are the way energy is
delivered. Biphasic energy is delivered
in two directions, whereas monophasic
energies are delivered in one direction.
Recommendations of the Interna-
tional Liaison Committee on Resuscita-
tion state that biphasic energies less
than or equal to 200 J are as efficacious
as escalating higher-energy monophasic
shocks.1 Lower-energy biphasic shocks
cause less myocardial injury and post-
resuscitation myocardial dysfunction,
and so potentially improve the likeli-
hood of survival.2 Faced with the lack of
data with respect to biphasic energy
levels, the Australian Resuscitation
Council makes the following recom-
mendations:
1. When using manual biphasic defi-
brillators, energy levels of 150 J
should be used for defibrillating ven-
tricular fibrillation and pulseless
ventricular tachycardia in adults.
The basis of this recommendation is
as follows: one randomised controlled
trial in people in out-of-hospital ven-
tricular fibrillation compared monopha-
sic and biphasic shocks delivered by
automated external defibrillators
(AEDs).3,4 This study showed that 150 J
biphasic shocks achieved higher rates of
defibrillation and return of spontaneous
circulation than higher-energy (200 J/
200 J/360 J) escalating monophasic
shocks. No differences were observed in
the proportion of patients discharged
from hospital.
As clinical superiority of one particu-
lar biphasic waveform over another has
yet to be demonstrated, it is appropriate
to recommend this single energy level to
achieve a consistent approach.
2. Biphasic energy levels of 1–2 J/kg
should be used for defibrillating ven-
tricular fibrillation and pulseless
ventricular tachycardia in children.
The basis of this recommendation is
as follows: extrapolation from adult
data, supported by studies in “child”
and “infant” animal models, suggests
that the dose for biphasic shocks in
children should be 1–2 J/kg (about half
the monophasic dose). Higher doses
(up to 4 J/kg) are not likely to be harm-
ful and are more efficacious than equiv-
alent monophasic shocks.5 Biphasic
shocks may be delivered in a fixed dose
of 50 J by an AED.
The use of AEDs in children less
than 1 year of age is not recommended,
as in this situation these devices are
unable to differentiate between shock-
able and non-shockable rhythms (eg,
ventricular fibrillation v pulseless elec-
trical activity).
Energy levels for AEDs when used in
automatic mode have been pre-set by
the manufacturer, and do not require an
energy level to be set by the user.
1. American Heart Association in collaboration with Interna-
tional Liaison Committee on Resuscitation. Guidelines 2000
for cardiopulmonary resuscitation and emergency cardio-
vascular care. Part 6: Advanced cardiovascular life sup-
port. Section 2: Defibrillation. Circulation 2000; 102 (Suppl
8): I90-I94.
2. Tang W, Weil MH, Sun S, et al. The effects of biphasic and
conventional monophasic defibrillation on postresuscitation
myocardial function. J Am Coll Cardiol 1999; 34: 815-822.
3. Schneider T, Martens PR, Paschen H, et al. Multicenter,
randomized, controlled trial of 150-J biphasic shocks com-
pared with 200- to 360-J monophasic shocks in the resusci-
tation of out-of-hospital cardiac arrest victims. Optimized
Response to Cardiac Arrest (ORCA) Investigators. Circula-
tion 2000; 102: 1780-1787.
4. Martens PR, Russell JK, Wolcke B, et al. Optimal Response
to Cardiac Arrest study: defibrillation waveform effects.
Resuscitation 2001; 49: 233-243.
5. Clark CB, Zhang Y, Davies LR, et al. Pediatric transthoracic
defibrillation: biphasic versus monophasic waveforms in an
experimental model. Resuscitation 2001; 51: 159-163. ❏
Tasmania: doing its 
wee bit for iodine nutrition
Judy A Seal,* Eric M Johnson,† 
Zelda Doyle,‡ Kelly Shaw§
* State Nutrition Officer, † State Food Officer, § Public 
Health Registrar, Public and Environmental Health, 
Department of Health and Human Services, GPO Box 
125, Hobart, TAS 7001; ‡ Field Officer, Broad Street 
Consultants, Tasmanian Iodine Monitoring Program, 
Lauderdale, TAS. judy.seal@dhhs.tas.gov.au
TO THE EDITOR: Tasmania has been
recognised for many years as an area of
endemic iodine deficiency.1 According
to the World Health Organization, pop-
ulations are considered iodine sufficient
if population median urinary iodine
(UI) levels exceed 100 mg/L, with less
than 10% of the UI levels below 50 mg/
L.2 Two random surveys (1998–99 and
2000–01) of Tasmanian school children
aged 4–14 years suggest mild iodine
deficiency. Median UI levels were
75g/L and 77g/L, with 13% and
21%, respectively, of the UI levels below
50g/L.3
In response to these findings, an
iodine supplementation program was
introduced in October 2001. Tasma-
nian bakeries were encouraged to switch
to using iodised salt in place of regular
salt. The program is voluntary, with
participating bakeries asked to sign a
memorandum of understanding. Indus-
try advice suggests that bakeries that
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have signed the memorandum produce
about 80% of the bread available for
consumption in Tasmania.
The Tasmanian Iodine Monitoring
Program commenced in July 2002. Its
objectives are to determine the effect of
iodine supplementation of bread on the
general population and on high-risk
groups, and to identify any negative
health effects associated with the pro-
gram.
Preliminary results from the monitor-
ing are encouraging. Children were
selected using a random cluster sam-
pling approach. The sampling frame
included all Grade 4 classes in all gov-
ernment, Catholic and independent
schools in Tasmania. To date, 148 urine
samples have been collected, with
results from 124 available (test comple-
tion rate, 84%). The median UI level
from the preliminary results is 97g/L
(95% CI, 90–109g/L), with 10.5%
below 50g/L. Ongoing monitoring
will provide a more rigorous evaluation
of the effects of the iodine supplementa-
tion program.
Early indications suggest the supple-
mentation program may be achieving its
goal of improving the iodine status of
the Tasmanian population. The moni-
toring program will continue for the
next 4 years, with regular surveys to
detect any changes in the population’s
iodine status. It will be challenging to
retain the ongoing participation of the
bread industry if, in the future, there is
increased reliance on premixed and
ready-to-bake products from outside
Tasmania. Maintaining bread supple-
mentation in Tasmania would then
require cooperation from interstate sup-
pliers to ensure iodine supplemention of
these premixes and ready-to-bake prod-
ucts. Given that recent research has
shown mild iodine deficiency in other
parts of Australia and New Zealand,
perhaps it is time for a bi-national solu-
tion to the problem.4,5
1. Gibson H. Surveillance of iodine deficiency disorders in
Tasmania 1949-1984. Hobart: Department of Health Serv-
ices, 1995.
2. World Health Organization. Assessment of iodine deficiency
disorders and monitoring their elimination: a guide for
programme managers. Geneva: WHO, 2001.
3. Hynes K. Urinary iodine status of Tasmanian primary school
children: final project report. Hobart: Menzies Centre for
Population Health Research, University of Tasmania, 2001.
4. Guttikonda K, Burgess JR, Hynes K, et al. Recurrent iodine
deficiency in Tasmania, Australia: a salutary lesson in sus-
tainable iodine prophylaxis and its monitoring. J Clin Endo-
crinol Metab 2002; 87: 2809-2815.
5. McDonnell CM, Harris M, Zacharin MR. Iodine deficiency
and goitre in schoolchildren in Melbourne, 2001. Med J Aust
2003; 178: 159-162. ❏
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TO THE EDITOR: The World Health
Organization has established the Glo-
bal Alliance for the Elimination of Lep-
rosy, which aims to eliminate leprosy
from every country by 2005.1 Elimina-
tion is defined as reducing the disease
prevalence to below one case per
10 000 population. Australia has met
this goal. Nevertheless, leprosy trans-
mission still occurs in parts of Aus-
tralia.
Between 1986 and 2002, 28 new
cases of leprosy were notified to the
Kimber ley  Publ i c  Heal th  Unit
(KPHU). All patients except one were
Indigenous. At diagnosis their ages
ranged from 8 to 63 years. In several
recent cases, diagnosis was delayed
despite multiple presentations to pri-
mary healthcare staff and medical spe-
cial is ts. Eleven patients (39%),
including the most recently diagnosed
case, had multibacillary disease (WHO
classifies leprosy as paucibacillary [< 6
skin lesions with no bacilli on skin
smears] or multibacillary [ 6 skin
lesions and/or positive skin smears]2).
People with multibacillary leprosy can
transmit the disease. This epidemiologi-
cal pattern is also seen in Australia’s
Northern Territory, where a third of the
236 new cases of leprosy between 1970
and 1997 were multibacillary.3 In lep-
rosy-endemic countries, the proportion
of cases that are multibacillary ranges
from 32% in Guinea to 84% in Egypt.4
The long incubation period of leprosy
(usually 2–5 years, but possibly dec-
ades) makes it likely that new cases will
occur in Australia over the next few
decades.
Management of patients in the Kim-
berley region is challenging, not only
because of remoteness, patient mobility
and the prolonged treatment and fol-
low-up required, but because adverse
reactions to leprosy treatment are com-
mon, and may occur weeks to months
after starting therapy with antileprotic
agents. With all presentations of lep-
rosy, the KPHU informs patients and
relevant health professionals about
these reactions, including how to recog-
nise them and where to seek specialist
advice. The region’s frequent turnover
of healthcare professionals and its
increasing reliance on short-term and
overseas-trained doctors makes this a
time-consuming undertaking.
With increasing movement of people
into and out of leprosy-endemic areas
like the Kimberley, or leprosy-endemic
countries, Indigenous Australians who
have not yet been exposed to leprosy
may now be at greater risk of encounter-
ing and acquiring the disease. In addi-
tion, Indigenous Australians from
leprosy-endemic areas may develop
symptoms of leprosy when they are no
longer in leprosy-endemic areas, and
may attend health professionals unfa-
miliar with leprosy, resulting in delayed
diagnosis.5
In the 21st century, the medical
community still needs to be alert to the
possibility of leprosy in patients with
chronic dermatological or neurological
conditions, and needs to enquire about
exposure to leprosy (eg, living in a
leprosy-endemic area, history of lep-
rosy in relatives — both by blood and
by marriage). Otherwise, we will fail to
diagnose and appropriately manage
this disease, risking further outbreaks
of leprosy in Indigenous Australian
populations.
1. World Health Organization. The final push strategy to elimi-
nate leprosy as a public health problem: Q & A. Geneva:
WHO, 2002.
2. Jacobson RR, Krahenbuhl JL. Leprosy. Lancet 1999; 353:
655-660.
3. Lush D, Hargrave JC, Merianos A. Leprosy control in the
Northern Territory. Aust N Z J Public Health 1998; 22:
709-713.
4. World Health Organization. Progress towards leprosy elimi-
nation. Wkly Epidemiol Rec 1998; 73: 153-160.
5. Archibald H, Fitzpatrick PF, Rée GH. Locally acquired
Hansen’s disease in North Queensland. Med J Aust 1999;
170: 72-73. ❏
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TO THE EDITOR: The recent study by
Wilson,1 and its accompanying editorial
by Walters and colleagues,2 highlight a
number of issues about written asthma
action plans (AAPs).
The utility of AAPs is controversial.
However, a number of points are more
certain:
■ AAPs will achieve nothing unless
they are part of a comprehensive pro-
gram of therapy, patient education and
review.
■ AAPs must be individualised, and
must cover several aspects of self-man-
agement, including ongoing mainte-
nance therapy and future acute episode
treatment (including the current epi-
sode if this has triggered the patient’s
attendance).
■ AAPs cannot improve patient care if
doctors don’t take the time and effort to
write them, and if patients don’t have
them available at the time of need,
particularly during acute episodes.
AAPs are a useful communication
tool, and an aid in consistency of care,
provided patients and all their doctors
have up-to-date copies of the same plan.
To help with the complex and time-
consuming task of producing custom-
ised AAPs, we developed a computer-
ised AAP generator which runs in a
standard web browser. Individualised
AAPs are produced with minimal typing
and a few mouse clicks in less than 45
seconds. All plans have sections for
future acute episodes. Sections for pre-
venter medications and the current epi-
sode only appear when selected. All
asthma medications currently available
in Australia are selectable from drop-
down menus, and these lists are
updated regularly. There are several
prompts to encourage best-practice
care.
Enough copies are produced for the
family, school, kindergarten, child
minder, grandparents, general practi-
tioner, and hospital notes.
The AAP generator was made avail-
able on the Royal Children’s Hospital
intranet in July 1999. This intranet ver-
sion logs, in detail, all use of the plan
and the recommended therapies, with-
out any patient identification. About
19 500 plans have been generated since.
We have not formally evaluated this
system, but we do know, from informal
feedback and from our records showing
that many of them have used it hun-
dreds of times each, that our staff find it
useful.
AAPs are only a part of the “educa-
tion package” required for patients with
asthma. If it is quick and easy to gener-
ate good AAPs, it is to be hoped this will
encourage doctors to produce them,
while also giving them more time to
concentrate on the explanation and dis-
cussion of care.
The AAP generator is available for
free download from our website
(www.rch.org.au/clinicalguide/asthma-
PlanRequest.php).
Acknowledgements: Members of the RCH Asthma Strategy
Group (Daryl Efron, Emma Gilbert, Ray Gornall, Claire Harris,
Gill Kainey, Andrew Kemp, John Massie, Frank Oberklaid, Colin
Powell, Colin Robertson, Susan Sawyer, Mimi Tang, Thirza
Titchen, Melissa Wake, Simon Young), Giles Bates (Paediatric
Fellow) and Marina Norio (Web author), all of whom contributed
to the concept and design of the plan.
1. Wilson DH, Adams RJ, Appleton SL, et al. Prevalence of
asthma and asthma action plans in South Australia: popu-
lation surveys from 1990 to 2001. Med J Aust 2003; 178:
483-485. 
2. Walters EH, Walters JA, Wood-Baker R. Why have asthma
action plans failed the consumer test? [editorial]. Med J
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TO THE EDITOR: I wish to report
hyponatraemia in a patient commencing
therapy with mirtazapine — this is the
first such report from Australia.
An 86-year-old widow with depres-
sion had had a previous episode of
hyponatraemia while taking venlafaxine.
Anticipating the possibility of further
hyponatraemia, I prescribed mirtaza-
pine 15 mg nightly — half the recom-
mended starting dose. At this time, she
was also taking amiodarone, gliclazide,
L -t hyrox ine ,  i rb e sa r t an  w i t h
hydrochlorothiazide, alendronate, ome-
prazole, atorvastatin and zolpidem.
Her baseline serum sodium level was
135 mmol/L (normal range [NR], 135–
149 mmol/L), but 4 days later it had
fallen to 130 mmol/L, with serum osmo-
lality of 294 mosmol/kg (NR, 280–
295 mosmol/kg), urine osmolality of
398 mosmol/kg (NR, 50–1200 mosmol/
kg), spot urine sodium concentration of
42 mmol/L, and plasma antidiuretic hor-
mone (ADH) level of 0.7 pmol/L (NR,
0.1–7.0 pmol/L). Mirtazapine therapy
was stopped after a further 2 days, and
10 days later her serum sodium level was
1 34 mmol /L ,  s e r um osmola l i ty
296 mosmol/kg, urine osmolali ty
419 mosmol/kg and spot urine sodium
concentration 27 mmol/L. Her plasma
glucose level varied from 7.4 mmol/L to
9.2 mmol/L (NR, 3.4–5.4 mmol/L). Her
condition was subsequently stabilised on
mianserin (20 mg nightly) without elec-
trolyte abnormalities.
There are 12 reports worldwide of
hyponatraemia due to mirtazapine
(manufacturer’s data “on file”). This
antidepressant inhibits 2 auto- and
heteroreceptors, blocks 5-HT2 and 5-
HT3 receptors, and acts via noradrener-
gic and 5-HT1A receptors. The mecha-
nism of hyponatraemia is thought to be
via 1 or serotonergic stimulation of
ADH, but other possible causes include
increased osmoreceptor sensitivity,
reduced renal ability to conserve salt
and water in the elderly, enhanced renal
action of ADH1 and reduced metabol-
ism of the antidepressant. There is no
known interaction between mirtazapine
and amiodarone or irbesartan or thi-
azides to account for hyponatraemia.
This patient had risk factors — she
was elderly, female, was taking diuretics
and had had hyponatraemia with
another antidepressant medication. As
in previously reported cases the ADH
level was not elevated, although the
syndrome of inappropriate ADH secre-
tion (SIADH) is not always accompan-
ied by raised ADH levels.2
Hyponatraemia is seen more often
these days because of greater awareness,
the increasing proportion of elderly peo-
ple in the population and the trend
towards polypharmacy in the elderly.
Many drugs have the potential to pro-
duce SIADH; one report has indicated
that almost all antidepressants are
implicated.3
Amitriptyline-induced hyponatraemia
was first described in 1974, and a recent
retrospective study of elderly patients
found an incidence of 32% with selec-
454 MJA Vol 179 20 October 2003
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tive serotonin reuptake inhibitors and
an unusually high 71% with venlafax-
ine.4
In the face of an increasingly com-
mon phenomenon, I recommend that
patients aged over 65 years should have
baseline  measurements of electrolyte
levels before starting therapy with an
antidepressant, and that these should
be repeated 2–7 days later to detect
possible hyponatraemia and initiate
treatment.
1. Helderman JH, Vestal RE, Rowe JW, et al. The response of
arginine vasopressin to intravenous ethanol and hypertonic
saline in man: the impact of aging. J Gerontology 1978; 33:
39-47.
2. Kirby D, Ames D. Hyponatraemia and selective serotonin
reuptake inhibitors in elderly patients. Int J Geriatr Psychia-
try 2001; 16: 484-493.
3. Spigset O, Hedenmalm K. Hyponatraemia in relation to
treatment with antidepressants: a survey of reports in the
WHO database for spontaneous reporting of adverse drug
reactions. Pharmacotherapy 1997; 17: 348-352.
4. Kirby D, Harrigan S, Ames D. Hyponatraemia in elderly
psychiatric patients treated with selective serotonin
reuptake inhibitors and venlafaxine: a retrospective control-
led study in an inpatient unit. Int J Geriatr Psychiatry 2002;
17: 231-237. ❏
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TO THE EDITOR: In a recent article by
Foran,1 information provided on the
new Essure (Conceptus, Inc) perma-
nent birth control or sterilisation
method was inaccurate in several
respects.
Firstly, Foran stated, incorrectly, that
the Essure method is performed laparo-
scopically (it is actually a hysteroscopic
method). This is a significant error, as
one of the unique advantages of this
method is the avoidance of incisional
surgery, particularly laparoscopy and a
general anaesthetic. This hysteroscopic
procedure is well tolerated and can be
performed with minimal or no sedation,
followed by a rapid postprocedure
recovery and early return to normal
activity.2,3
Secondly, the failure rate in terms of
postprocedure pregnancy is much less
than the 0.6% quoted by Foran. To
date, no pregnancies have been
recorded in Phase II2 or Phase III3
multicentre, prospective, single-arm
clinical trials conducted according to
US Food and Drug Administration
guidelines between 1998 and 2003. To
date, no pregnancies have occurred in
women relying on this intratubal micro-
insert during a combined 15 635
women-months of follow-up. The effec-
tiveness rate for pregnancy prevention
after 2 years of follow-up is 100% (95%
CI, 99.5%–100%).
Thirdly, it is not a titanium insert.
The metal used in the outer dynamic
coil is a nickel–titanium alloy commonly
known by the trade name Nitinol.
Fourthly, the adverse effects claimed
(infection, bleeding) are misleading and
incorrect. No infections within the
uterus, tubes or pelvis have been
recorded, and abnormal bleeding is not
a feature of this form of sterilisation.2,3
Essure is the first hysteroscopic
method of female sterilisation to gain
regulatory approval for clinical use (in
November 2002). This method of steri-
lisation offers women the choice of a
less invasive, safe and reliable choice of
sterilisation in the future.
Competing interests: John Kerin is a clinical research investi-
gator and consultant and holds an equity position in Conceptus
Inc.
1. Foran TM. New contraceptive choices across reproductive
life. Med J Aust 2003; 178: 616-620.
2. Kerin JF, Cooper JM, Price T, et al. Hysteroscopic steriliza-
tion using a micro-insert device: results of a multicentre
Phase II study. Hum Reprod 2003; 18: 1223-1230.
3. Cooper JM, Carignan CS, Cher D, Kerin JF. Microinsert
nonincisional hysteroscopic sterilization. Obstet Gynecol
2003; 102: 59-67. ❏
Therese M Foran
Medical Director, FPA Health, 328–336 Liverpool Road, 
Ashfield, NSW 2131. terrifash@fpahealth.org.au
IN REPLY: Mea culpa! Essure is, of
course, a hysteroscopic rather than a
laparoscopic method of female sterilisa-
tion and is described so in the text of the
article. I apologise for not picking up
this error while checking the proofs.
Kerin is also correct in pointing out that
Essure is made not from pure titanium
but from a titanium alloy. The possible
adverse effects, though rare, are listed
among a number of others in the manu-
facturer’s information brochure.1
I am always extremely wary of ascrib-
ing a 100% effectiveness rate to any
contraceptive method. Since Essure has
been used so far on only small numbers
of women, the figure I quoted was the
upper limit of the failure rate in world
literature for female sterilisation pro-
cedures.2 Although initial experience
indicates that the eventual success rate
should be very close to 100%, Kerin’s
quoted 95% CI suggests that, at
present, we can only promise potential
Essure users a better than 99.5% effec-
tiveness rate (ie, a failure rate quite close
to the figure I used).
I consider Essure to be an excellent
new method of permanent contracep-
tion, and apologise if my article gave
any other impression. I am certain that
Australian women and their doctors will
increasingly consider it an option in the
future.
1. The Essure pbc procedure. A new method of permanent
birth control now available in Australia [product information
brochure]. Conceptus, 2001.
2. Guillebaud J. Contraception: your questions answered. 3rd
ed. London: Churchill Livingstone, 1999. ❏
Update on treatment of 
menstrual disorders
David H Eizenberg
Obstetrician and Gynaecologist, Macquarie 
Chambers, 183 Macquarie Street, Sydney, NSW 2000
TO THE EDITOR: In their recent article
on treatment of menstrual disorders,
Hickey and Farquhar described three
case scenarios to highlight alternative
treatments for menstrual disorders.1
In Patient 1, a 39-year-old woman with
dysfunctional uterine bleeding, the
authors preferentially treated the patient
with the levonorgestrel-releasing intrau-
terine system (20g per 24 h). Unfortun-
ately, this device is available through the
Pharmaceutical Benefits Scheme only for
contraception, not treatment of menor-
rhagia. It would be difficult to explain to
the government its use in this woman,
who, according to the history, had had
laparoscopic sterilisation. As a new intra-
uterine system has to be inserted every 5
years, and has a failure rate of 20% after 1
year, a 39-year-old woman would need at
least another two inserted to control dys-
functional bleeding.
The optimum method of management
would have been simple vaginal hysterec-
tomy. This was not mentioned in the
article, which contrasted the intrauterine
system only with abdominal hysterec-
tomy. The authors also claimed that
“cost–benefit analysis showed that [the
intrauterine system] Mirena was three
times cheaper than hysterectomy”. This
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analysis should include the cost of three
Mirenas ($260 each), insertion, doctors’
visits for Pap smears for 30 years, tam-
pons and pads. Is this cheaper? After all,
hysterectomy means no periods, pain,
pregnancies, Pap smears or pads.
What is wrong with vaginal hysterec-
tomy? The fact that the woman had
had three caesarean sections and lapar-
oscopic sterilisation was not a contra-
indication.2
Patient 2, a 45-year-old woman with
menorrhagia and small fibroids, could
also have been managed with vaginal
hysterectomy.3 There is no evidence
that hysteroscopic resection of fibroids
in a multiple-fibroid uterus, as recom-
mended by the authors, will improve
menorrhagia. They also state that an
alternative technique, embolisation, has
been “widely used”. This technique is
experimental and, as they state, “has
been associated with serious side
effects, such as infection, bowel
obstruction and loss of ovarian func-
tion”, as well as death.4
In our quest for management innova-
tions for women with dysfunctional
bleeding, we should decide whether the
new technique is better than the gold
standard, hysterectomy. As hysterec-
tomy can be vaginal, laparoscopic with
vaginal assistance, totally laparoscopic,
or abdominal, one cannot just use the
word “hysterectomy”, one must specify.
Studies reveal that the vaginal approach
is superior.2,5
1. Hickey M, Farquhar CM. Update on treatment of menstrual
disorders. Med J Aust 2003; 178: 625-629. 
2. Sheth SS, Studd J, editors. Vaginal hysterectomy. London:
Martin Dunitz 2002: 315-320.
3. Eizenberg DH. Goserelin. Reduction of uterine fibroids
before vaginal hysterectomy. Aust N Z J Obstet Gynaecol
1995; 1: 109-110.
4. Vashisht A, Studd J, Carey A, et al. Embolisation: a tech-
nique not without significant complications. Br J Obstet
Gynaecol 2000; 107: 1166-1170.
5. Summit RL Jr, Stoval TG, Lipscom BGH, Ling FW. Ran-
domised comparison of laparoscopically-assisted hysterec-
tomy with standard vaginal hysterectomy in an outpatient
setting. Obstet Gynecol 1992; 80: 895-901. ❏
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IN REPLY: Eizenberg is correct in stating
that the levonorgestrel-releasing intra-
uterine system Mirena is currently
licensed as a contraceptive in Australia
and not explicitly for treatment of men-
strual disorders. He is also correct in
stating that vaginal hysterectomy would
be a management option for Cases 1
and 2 in our article.1
However, the purpose of our article
was to explore newer options in man-
agement of menstrual disorders. This
does not mean that “traditional”
therapies such as hysterectomy are to be
overlooked or superseded, and we did
not attempt to compare the new therap-
ies with hysterectomy. Dysfunctional
uterine bleeding, although disruptive, is
a benign condition, and treatment is
symptomatic. We believe that women
should be aware of all available thera-
peutic options, including hysterectomy,
so that they can reach an informed
decision.
1. Hickey M, Farquhar CM. Update on treatment of menstrual
disorders. Med J Aust 2003; 178: 625-629. ❏
Latrodectism: a prospective 
cohort study of bites by 
formally identified redback 
spiders
Saul Wiener
Allergist, Royal Melbourne Hospital, 46 Balaclava 
Road, East St Kilda, VIC 3183.
TO THE EDITOR: In their study on the
effectiveness of antivenom for redback
spider bite, Isbister and Gray cast doubt
on the current method of administering
antivenom intramuscularly.1
Any study on the outcome of treating
bites by venomous animals is limited by
factors beyond the control of the investi-
gator. These include the variability of the
venom content in the animal’s venom
apparatus, uncertainty regarding how
much and where venom has been
injected, and the delay before treatment.
Between 1955 and 1957, I dissected
the venom glands of 590 redback spi-
ders for the production of antivenom.2
The yield of freeze dried venom per
spider varied from 0.08 mg to 0.32 mg.
Based on these findings, and to allow
for dilution of antivenom by body flu-
ids, “it was considered that 500 units of
antivenene would constitute a suitable
initial dose for the treatment of a bite by
L. hasseltii”.3 This amount of antivenom
will neutralise 5 mg of venom in vitro,
and the antivenom is still issued in this
strength by CSL Ltd.
No fatalities have occurred from red-
back spider bite since antivenom
became available in 1956,4 and reports
from doctors have confirmed its efficacy
and safety.5 If symptoms persist after
the initial dose, or if diagnosis has been
delayed, the initial dose of 500 units
may have to be repeated. As Banham et
al have wisely stated “treatment should
be titrated against response”.6
Because of the risk of anaphylaxis,
intramuscular injection, which has
stood the test of time, is safer than the
intravenous route.
1. Isbister GK, Gray MR. Latrodectism: a prospective cohort
study of bites by formally identified redback spiders. Med J
Aust 2003; 179: 88-91. 
2. Wiener S. The Australian red back spider (Latrodectus
hasseltii) I. Preparation of antiserum by the use of venom
adsorbed on aluminium phosphate. Med J Aust 1956; 1:
739-742.
3. Wiener S. Red back spider antivenene. Med J Aust 1961; 2:
41-43.
4. Sutherland SK. Spider bites in Australia. Med J Aust 1983;
2: 597.
5. Sutherland SK, Trinca KC. Survey of 2144 cases of red-back
spider bites. Med J Aust 1978; 2: 620-623.
6. Banham NDG, Jelinek GA, Finch PM. Late treatment with
antivenom in prolonged red-back spider envenomation.
Med J Aust 1994; 161: 379-381. ❏
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IN REPLY: We thank Wiener for his
comments on our study. Although we
challenge the use of intramuscular red-
back spider antivenom (RBS AV) in the
article, we only suggested that the use of
intramuscular antivenom needs review
and that randomised controlled trials
comparing intravenous and intramuscu-
lar RBS AV should be undertaken. Two
such trials, in Western Australia and
Newcastle, are currently in progress.
There are no pharmacokinetic studies
of RBS AV, but studies of other antiven-
oms suggest that the intramuscular
route is less effective.1 In Tunisia, the
in t ramuscular  use  of  scor pion
antivenom, which is also an F(ab)2
antivenom, similar to RBS AV, has been
questioned for similar reasons.2,3 Stud-
ies in a rabbit model demonstrated that
intramuscular antivenom induced only
partial and delayed neutralisation of cir-
culating toxins.3 More importantly, in a
study of scorpion stings of children,
the intramuscular administration of
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antivenom had far less effect on plasma
venom concentrations and patient
recovery times.2
We do not dispute that repeated doses
of antivenom may be required, but the
implication that only an initial dose was
used in our study is incorrect. Half of
the treated patients required repeat
doses (6 ampoules in one patient). In a
recent series of four patients with red-
back spider bites, intramuscular
antivenom was ineffective, even though
three patients received two or three
ampoules. Subsequent intravenous
antivenom was effective in all cases.4
There is no evidence that appropriately
administered intravenous RBS AV
(diluted in 200 mL of normal saline,
over 20–30 minutes) is less safe than
intramuscular antivenom. There is
insufficient reason to prevent the use of
intravenous antivenom if it is shown to
be more effective than intramuscular
antivenom. Although it is too early to
change recommendations for the
administration of RBS AV, it is essential
that controlled trials be done.
1. Riviere G, Choumet V, Audebert F, et al. Effect of antivenom
on venom pharmacokinetics in experimentally envenomed
rabbits: toward an optimization of antivenom therapy. J
Pharmacol Exp Ther 1997; 281: 1-8.
2. Krifi MN, Amri F, Kharrat H, El Ayeb M. Evaluation of
antivenom therapy in children severely envenomed by
Androctonus australis garzonii (Aag) and Buthus occitanus
tunetanus (Bot) scorpions. Toxicon 1999; 37: 1627-1634.
3. Krifi MN, Miled K, Abderrazek M, El Ayeb M. Effects of
antivenom on Buthus occitanus tunetanus (Bot) scorpion
venom pharmacokinetics: towards an optimization of
antivenom immunotherapy in a rabbit model. Toxicon 2001;
39: 1317-1326.
4. Isbister GK. Failure of intramuscular antivenom in redback
spider envenomation. Emerg Med 2002; 14: 436-439. ❏
Breast self-examination: 
be alert but not alarmed?
John Boyages
Executive Director, New South Wales Breast Cancer 
Institute, PO Box 143, Westmead, NSW 2145. 
johnb@bci.org.au
TO THE EDITOR: I read with interest
the position paper on breast self-exam-
ination by Crossing and Manaszewicz.1
I would like to point out an error of
fact. The New South Wales Breast Can-
cer Institute (NSW BCI) has been pro-
moting breast self-examination for
many years.
As a practising clinician, every month
I see several women who have found
small breast cancers using instructions
from an old New Idea shower card or
similar information.
The position of the NSW BCI, which
is stated clearly on our website, is as
follows:
■ Women should consider an annual
breast examination by their general
practitioner, particularly when they
attend for a Pap test or a blood pressure
check.
■ Mammography should be performed
at least every 2 years, particularly for
women over 50 years, and earlier for
women with a family history of breast
cancer.
■ Women should practise regular
breast self-examination (BSE). Infor-
mation about BSE can be obtained
from GPs and the BCI has produced a
fact sheet (www.bci.org.au/public/
guides/g8bse.htm).
■ BSE costs nothing and, in our opin-
ion, does more good than harm. How-
ever, BSE should be combined with
regular mammography and an examina-
tion by a GP.
■ For a woman with a family history of
breast cancer, or who has been diag-
nosed with breast cancer, BSE can be
helpful in finding disease.
■ Mammography is only about 95% reli-
able. BSE complements mammography.
Certain types of breast cancer are
often difficult to diagnose with mam-
mography, for example “lobular” can-
cer, and BSE may help in finding such
cancers.
No evidence has been published that
would justify a change in this position.
1. Crossing S, Manaszewicz R. Breast self examination: be
alert but not alarmed? Med J Aust 2003; 178: 646-647. ❏
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